unlik
tradit
liveattenu
inactivatedkil
viru
vaccin
need
cultiv
infecti
virion
recombin
proteinbas
nonrepl
subunit
vaccin
involv
infecti
agent
product
process
therefor
consid
safer
tradit
vaccin
fact
mani
virus
human
norovirus
hunov
cultiv
effici
make
vaccin
develop
hunov
difficult
therefor
subunit
vaccin
choic
case
highli
virul
virus
polioviru
variola
viru
riski
cultiv
larg
scale
make
subunit
vaccin
approach
safer
choic
scenario
subunit
vaccin
approach
help
includ
develop
vaccin
malaria
caus
larg
protozoan
parasit
noninfecti
diseas
caus
certain
protein
factor
human
hypertens
cancer
circumst
selfassembl
polyval
highli
immunogen
viral
particl
protein
polym
use
platform
increas
immunogen
specif
antigen
pathogen
protein
factor
caus
diseas
chimer
vaccin
combin
subunit
vaccin
design
use
mono
bi
even
trival
vaccin
one
pathogen
andor
diseas
develop
product
subunit
combin
subunit
vaccin
wellestablish
express
system
includ
recombin
bacteria
yeast
baculoviru
insect
cell
andor
variou
viral
plasmid
vector
mammalian
avian
plant
cell
consid
costeffect
compar
tradit
liveattenu
inactivatedkil
viru
vaccin
thu
subunit
vaccin
approach
would
help
extend
vaccin
distribut
wide
develop
countri
remot
area
vaccin
usual
highli
demand
longcours
evolut
virus
develop
common
featur
assembl
effici
viral
replic
viral
structur
protein
abl
spontan
assembl
spheric
rodshap
capsid
viral
capsid
protein
produc
host
cell
basic
drive
forc
behind
selfassembl
capsid
homotyp
interact
viral
capsid
protein
mani
case
heterotyp
interact
also
requir
assembl
complex
capsid
compos
one
viral
structur
protein
uniqu
featur
viral
structur
protein
util
gener
variou
viruslik
particl
vlp
small
subvir
particl
andor
protein
polym
vitro
fig
one
wellestablish
recombin
protein
express
system
date
least
differ
vlp
small
subvir
particl
andor
polym
repres
viral
famili
gener
review
see
ref
gener
product
singl
major
viral
capsid
protein
appropri
express
system
lead
format
correspond
vlp
exampl
express
major
hunov
capsid
protein
via
recombin
baculovirus
inset
cell
form
hunov
current
gener
vlp
made
singl
capsid
protein
review
howev
case
one
capsid
protein
requir
assembl
complex
vlp
instanc
doublelay
vlp
rotaviru
rv
made
coexpress
protein
use
baculoviru
express
triplelay
rv
vlp
gener
constitut
coexpress
stabli
transfect
insect
cell
complex
recombin
vlp
sever
acut
respiratori
syndrom
coronaviru
sarscov
vlp
made
coexpress
structur
protein
includ
spike
envelop
e
membran
nucleocapsid
n
protein
simultan
use
baculoviru
data
suggest
vlp
virus
may
also
gener
base
selfassembl
principl
appropri
express
approach
contrast
small
subvir
particl
also
construct
gener
truncat
viral
structur
protein
exampl
differ
hunov
protrud
p
particl
selfassembl
modifi
p
domain
hunov
capsid
protein
gener
via
bacteri
express
system
includ
p
small
p
larg
p
stabil
p
particl
enhanc
artifici
introduc
disulfid
bond
core
p
particl
via
endlink
cysteinecontain
peptid
p
similarli
express
truncat
domain
hepat
e
viru
hev
form
nmparticl
name
addit
homotyp
interact
featur
viral
structur
protein
also
employ
gener
differ
protein
polym
dna
recombin
technolog
fig
includ
lineag
polym
fusion
dimer
protein
togeth
network
polym
via
fusion
dimer
protein
coval
agglomer
polym
fusion
oligomer
protein
dimer
protein
fig
drive
forc
behind
protein
polym
format
intermolecular
dimer
andor
oligomer
among
homolog
protein
differ
vlp
small
subvir
particl
protein
polym
studi
vaccin
candid
see
artifici
made
vlp
small
subvir
particl
viral
protein
polym
maintain
basic
molecular
pattern
major
b
tcell
epitop
parent
virus
highli
immunogen
polyval
natur
thu
abl
elicit
potent
innat
humor
cellular
immun
among
differ
particl
polym
vlp
first
develop
character
subunit
vaccin
review
far
sever
vlpbase
vaccin
commerci
avail
human
use
global
includ
human
papillomaviru
hpv
vlp
vaccin
consist
protein
major
capsid
protein
prevent
cervic
anogenit
infect
diseas
associ
hpv
merck
co
new
jersey
usa
glaxosmithklin
london
uk
hepat
b
virus
hbv
vlp
vaccin
compos
small
surfac
antigen
hbv
hbsag
hbv
infect
recombivax
merck
co
new
jersey
usa
glaxosmithklin
london
uk
addit
small
subvir
particl
vaccin
form
truncat
domain
hev
capsid
protein
recent
develop
hev
vaccin
human
china
hev
xiamen
innovax
biotech
xiamen
china
success
vlp
small
subvir
particl
vaccin
endow
feasibl
use
subunit
vaccin
approach
addit
subunit
vaccin
approv
commerci
use
mani
other
develop
among
hunov
vlp
parvoviru
vlp
reach
stage
clinic
trial
addit
use
vaccin
individu
viral
pathogen
selfassembl
highli
stabl
highli
immunogen
vlp
small
subvir
particl
protein
polym
also
excel
vaccin
platform
combin
vaccin
develop
one
pathogen
diseas
foreign
antigen
epitop
incorpor
onto
vlp
small
subvir
particl
protein
polym
immunogen
result
chimer
combin
subunit
vaccin
pathogen
provid
platform
insert
antigen
epitop
fig
vaccin
rt
mosquirix
glaxosmithklin
london
uk
malaria
one
combin
vaccin
reach
market
consist
hbv
hbsag
contain
portion
plasmodium
falciparumderiv
circumsporozoit
protein
csp
liposomebas
note
although
mosquirix
approv
european
medicin
agenc
ema
activ
immun
children
age
week
month
malaria
world
health
organ
recommend
inclus
vaccin
expand
programm
immunis
epi
due
rapidli
declin
vaccin
protect
particularli
infant
potenti
risk
mening
advers
combin
vaccin
base
principl
also
develop
reach
stage
clinic
trial
exampl
vaccin
cyto
biotechnolog
ag
schlieren
switzerland
consist
vlp
coval
coupl
angiotensin
ii
epitop
therapeut
treatment
hypertens
reach
phase
ii
clinic
anoth
exampl
vaccin
nicvax
nabi
biopharmacetu
rockvil
maryland
compos
nicotin
form
hapten
conjug
exoprotein
complex
pseudomona
reduc
elimin
physic
depend
nicotin
reach
phase
iii
clinic
trial
http
phxcorporateirnetphoenixzhtml
pirolnewsarticl
highlight
exampl
vaccin
vaxinn
cranburi
new
jersey
recombin
flagellin
protein
ligand
tandem
copi
epitop
influenza
viru
fuse
phase
ii
clinic
trial
ongo
test
efficaci
vaccin
univers
vaccin
influenza
viru
http
wwwbiocenturycomcompaniesvaxinnatecorp
base
principl
small
subvir
particl
also
use
platform
combin
vaccin
develop
exampl
nov
p
particl
contain
surfac
loop
shown
abl
hold
foreign
antigen
epitop
without
compromis
stabil
chimer
p
rv
neutral
antigen
influenza
viru
epitop
human
immunodefici
viru
hiv
epitop
enteroviru
insert
onto
surfac
loop
p
particl
chimer
p
particl
vaccin
preclin
anim
trial
vaccin
candid
reveal
high
antibodi
titer
specif
insert
antigenepitop
p
particl
platform
respect
protect
vaccin
mice
infect
influenza
data
indic
hunov
p
particl
excel
platform
combin
vaccin
develop
combin
vaccin
develop
includ
type
viral
protein
polym
fig
see
exampl
fusion
dimer
p
domain
hunov
hev
major
neutral
antigen
virus
fig
form
lineag
polym
fig
result
bival
vaccin
similarli
fusion
p
domain
hunov
hev
astroviru
astv
major
neutral
antigen
virus
fig
form
network
polym
fig
lead
trival
vaccin
furthermor
hunov
p
domain
modifi
oligomer
protein
via
endlink
cysteinecontain
fuse
dimer
protein
form
agglomer
polym
lead
combin
vaccin
hunov
select
fact
monomer
antigen
rv
antigen
epitop
influenza
viru
also
incorpor
polym
enhanc
immunogen
combin
vaccin
preclin
anim
trial
viral
polymerbas
combin
vaccin
show
good
immun
respons
neutral
activ
hunov
hev
well
protect
vaccin
mice
infect
influenza
develop
effect
nonrepl
subunit
vaccin
base
mani
known
neutral
antigen
epitop
face
common
issu
low
immunogen
due
rel
small
size
low
valenc
antigensepitop
issu
solv
fuse
antigen
epitop
onto
larg
polyval
highli
immunogen
vlp
small
subvir
particl
protein
polym
platform
improv
immunogen
combin
vaccin
success
combin
vaccin
report
challeng
also
encount
gener
larger
antigen
contain
authent
antigen
featur
immunogen
less
compat
viral
particlebas
platform
compar
smaller
epitop
easier
incorpor
onto
viral
particl
without
compromis
stabil
result
chimer
vaccin
therefor
balanc
factor
need
consid
best
vaccin
outcom
among
differ
vaccin
platform
vlp
small
subvir
particl
usual
form
unifi
particl
incorpor
foreign
antigen
better
qualiti
control
compar
protein
polym
howev
viral
particlebas
platform
gener
limit
surfac
space
foreign
antigenepitop
insert
fig
may
lead
instabl
chimer
vaccin
hand
protein
polym
made
differ
antigen
fig
thu
exhibit
much
larger
capac
flexibl
incorpor
larger
antigen
howev
result
polym
size
may
dispers
may
need
better
qualiti
control
unifi
vaccin
outcom
summari
develop
differ
vaccin
platform
favor
featur
continu
identif
new
effect
antigen
epitop
facilit
advanc
combin
subunit
vaccin
differ
human
diseas
